Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Retained Earnings (2020 - 2025)

Maravai Lifesciences Holdings (MRVI) has 6 years of Retained Earnings data on record, last reported at $10.1 million in Q4 2025.

  • For Q4 2025, Retained Earnings changed N/A year-over-year to $10.1 million; the TTM value through Dec 2025 reached $10.1 million, changed N/A, while the annual FY2025 figure was $10.1 million, N/A changed from the prior year.
  • Retained Earnings reached $10.1 million in Q4 2025 per MRVI's latest filing, down from $45.8 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $404.8 million in Q4 2022 and bottomed at $10.1 million in Q4 2025.
  • Average Retained Earnings over 5 years is $220.2 million, with a median of $251.4 million recorded in 2022.
  • Peak YoY movement for Retained Earnings: soared 21511.36% in 2021, then plummeted 73.18% in 2025.
  • A 5-year view of Retained Earnings shows it stood at $184.6 million in 2021, then surged by 119.31% to $404.8 million in 2022, then dropped by 29.41% to $285.7 million in 2023, then crashed by 41.63% to $166.8 million in 2024, then plummeted by 93.93% to $10.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were $10.1 million in Q4 2025, $45.8 million in Q3 2025, and $71.4 million in Q2 2025.